Evidence map›Paper›PMID 27001822›Full record

Trial reportAntimicrobial agents and chemotherapy2016

Successful Salvage of Central Venous Catheters in Patients with Catheter-Related or Central Line-Associated Bloodstream Infections by Using a Catheter Lock Solution Consisting of Minocycline, EDTA, and 25% Ethanol.

Issam Raad, Anne-Marie Chaftari, Ramia Zakhour, Mary Jordan, Zanaib Al Hamal, Ying Jiang, Ammar Yousif, Kumait Garoge, Victor Mulanovich, George M Viola and 4 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase II
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01539343 (Phase II Pilot Study to Estimate the Adverse Events Associated With the Lock Solution When Used to Salvage Central Venous Catheter), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01539343 phase2completednot on this map

Phase II Pilot Study to Estimate the Adverse Events Associated With the Lock Solution When Used to Salvage Central Venous Catheter (CVC) in the Setting of a Central Line Associated Bloodstream Infection (CLABSI)

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2013 to 2016Enrolled31ConditionsInfectionArmsAntimicrobial Solution
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. ACS applied materials & interfaces · 2021
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Issam RaadMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA iraad@mdanderson.org.
Anne-Marie ChaftariMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
Ramia ZakhourMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
Mary JordanMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
Zanaib Al HamalMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
Ying JiangMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
Ammar YousifMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
Kumait GarogeMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
Victor MulanovichMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
George M ViolaMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
Soha KanjMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
Egbert PravinkumarMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
Joel RosenblattMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
Ray HachemMD Anderson Cancer Center, Department of Infectious Diseases, Infection Control & Employee Health, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In cancer patients with long-term central venous catheters (CVC), removal and reinsertion of a new CVC at a different site might be difficult because of the unavailability of accessible vascular sites. In vitro and animal studies showed that a minocycline-EDTA-ethanol (M-EDTA-EtOH) lock solution may eradicate microbial organisms in biofilms, hence enabling the treatment of central line-associated bloodstream infections (CLABSI) while retaining the catheter in situ Between April 2013 and July 2014, we enrolled 30 patients with CLABSI in a prospective study and compared them to a historical group of 60 patients with CLABSI who had their CVC removed and a new CVC inserted. Each catheter lumen was locked with an M-EDTA-EtOH solution for 2 h administered once daily, for a total of 7 doses. Patients who received locks had clinical characteristics that were comparable to those of the control group. The times to fever resolution and microbiological eradication were similar in the two groups. Patients with the lock intervention received a shorter duration of systemic antibiotic therapy than that of the control patients (median, 11 days versus 16 days, respectively; P < 0.0001), and they were able to retain their CVCs for a median of 74 days after the onset of bacteremia. The M-EDTA-EtOH lock was associated with a significantly decreased rate of mechanical and infectious complications compared to that of the CVC removal/reinsertion group, who received a longer duration of systemic antimicrobial therapy. (This study has been registered at ClinicalTrials.gov under registration no. NCT01539343.).

Indexed as

AdultAgedAnti-Bacterial AgentsBacteremiaBiofilmsCatheterization, Central VenousCatheter-Related InfectionsCentral Venous CathetersEdetic AcidEthanolFemaleHumansMaleMiddle AgedMinocyclineNeoplasmsAnti-Bacterial AgentsEdetic AcidEthanolMinocycline

Identifiers

PMID27001822
PMCPMC4879419
OpenAlexW2306762654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.